BMEYE(TM) Announces CE Mark Approval
23/07/2007 09:05
PR Newswire
AMSTERDAM, July 23 /PRNewswire/ -- BMEYE(TM) announced today CE Mark approval of Nexfin(TM),
their newly developed line of accurate and easy to use hemodynamic monitors.
The Nexfin(TM) monitors provide accurate and easy to use continuous
non-invasive blood pressure and cardiac output monitoring.
"BMEYE(TM) was established to develop and market innovative
technology that will transform the practice of medicine in hemodynamic
patient monitoring. We are pleased and gratified by the CE Mark approval
enabling us to market the Nexfin(TM) to cardiologists and any clinician who
needs to measure continuous non-invasive blood pressure and cardiac output
easily and accurately", said Bill Bednarski, CEO of BMEYE(TM). "The
Nexfin(TM) is cost effective and will significantly improve patient care."
BMEYE(TM), based in Amsterdam and St. Louis, develops and
markets innovative medical technology with broad applications in a variety of
clinical settings. The focus of BMEYE(TM) is on accurate and easy to use
non-invasive hemodynamic monitoring. The Nexfin(TM) family of monitors use an
easy to apply finger sensor to produce accurate continuous non-invasive blood
pressure and cardiac output data displayed on an intuitive touchscreen.
Patents pending. For more information please check our web
site at www.bmeye.com.
Contact Information: Bill Bednarski, CEO BMEYE, Academic Medical Center, Suite K2-245, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands, Phone: +31-(0)20-566-7720, Email: bill.bednarski@bmeye.com; Center for Emerging Technologies, 4041 Forest Park Avenue, St. Louis, Missouri, 63108, USA, Phone: +1-(925)270-0741